Download Files:
NLRP3-IN-13
$150 – $1,350
Products Details
Product Description
– NLRP3-IN-13 (Compound C77 in reference patent) is a selective and potent NLRP3 inhibitor (IC50: 2.1 μM). NLRP3-IN-13 inhibits NLRP3 andNLRC4 inflammasomes, and inhibits NLRP3-mediated IL-1β production. NLRP3-IN-13 also inhibits NLRP3 ATPase activity. NLRP3-IN-13 can be used in the research of neuroinflammatory disorders[1].
Web ID
– HY-150206
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C19H15N3O3S
References
– [1]Devita Robert, et al. Benzoxazolones as inhibitors of inflammasomes and their preparation. Patent. WO2022187804.
CAS Number
– 1704638-35-6
Molecular Weight
– 365.41
Compound Purity
– 99.01
SMILES
– O=C1OC2=C(N1CC(NCC3=CN=CC(C4=CSC=C4)=C3)=O)C=CC=C2
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Neurological Disease
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– NOD-like Receptor (NLR)
Isoform
– NLRP3
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
